Dermatology and Therapy最新文献

{"title":"Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure.","authors":"Lawrence Green, April Armstrong, George Han, Abby Jacobson","doi":"10.1007/s13555-025-01533-9","DOIUrl":"https://doi.org/10.1007/s13555-025-01533-9","url":null,"abstract":"<p><p>This narrative review evaluates the clinical evidence supporting brodalumab as a second-line therapy against moderate-to-severe plaque psoriasis in adults who have experienced prior systemic treatment failure. Despite advances in biologic therapy, treatment failure remains a substantial challenge, with patients often discontinuing initial biologic treatment owing to inadequate response. Here, we analyzed data from clinical trials, real-world studies, and observational research examining brodalumab's efficacy in treatment-experienced populations. Unlike other biologics that target specific interleukin 17 (IL-17) cytokines, brodalumab blocks the IL-17 receptor A and prevents signaling from multiple IL-17 family members, potentially explaining its effectiveness in treatment-resistant cases. The evidence presented here demonstrates rapid Psoriasis Area and Severity Index response rates, as well as durable efficacy of brodalumab in patients after a failed treatment with previous biologic therapies. This narrative review synthesizes the current evidence base for brodalumab's role specifically in the second-line setting, providing clinicians with a comprehensive assessment of its efficacy in treatment-resistant psoriasis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ChinaSTAD Chinese Registry in Patients with Moderate-To-Severe Atopic Dermatitis Not Controlled by Topical Therapy: Baseline Characteristics, Disease Burden and Treatment.","authors":"Ping Liu, Bingjiang Lin, Yanna Shen, Yonghong Lu, Jingyi Li, Dong Lv, Xu Yao, Xiaoyong Man, Hong Fang, Guan Jiang, Nan Yu, Dongmei Liu, Siyan Zhan, Jianzhong Zhang","doi":"10.1007/s13555-025-01540-w","DOIUrl":"https://doi.org/10.1007/s13555-025-01540-w","url":null,"abstract":"<p><strong>Introduction: </strong>In China, real-world evidence on the burden and management of moderate-to-severe atopic dermatitis (AD) is needed. The ChinaSTAD study aimed to characterise the treatment and disease and health economic burden of patients with moderate-to-severe AD uncontrolled on topical therapy in China.</p><p><strong>Methods: </strong>The ChinaSTAD national prospective registry study enrolled individuals aged ≥ 12 years with AD, with a SCORing Atopic Dermatitis (SCORAD) score of ≥ 25, at participating hospitals. At baseline (enrolment visit), clinical status (SCORAD, Patient-Oriented Eczema Measure [POEM], Peak Pruritus Numerical Rating Scale [PP-NRS], Atopic Dermatitis Control Tool [ADCT]), health-related quality of life (Dermatology Life Quality Index [DLQI] and Children's DLQI [CDLQI]), AD treatment, and healthcare resource use in the previous year, were evaluated. Costs were estimated from the patient's perspective. Baseline visit data are reported here for the subgroup of patients who had not received prior systemic AD therapy continuously up to the point of study enrolment. Data are expressed as mean ± standard deviation unless stated otherwise.</p><p><strong>Results: </strong>Of 2962 patients enrolled at data cut-off (31 October 2022), 2550 were included in this analysis (aged 40.2 ± 21.0 years). The baseline SCORAD was 54.4 ± 15.7; 85.6% of patients had uncontrolled AD (ADCT score ≥ 7), and DLQI and CDLQI scores were 10.9 ± 7.1 and 9.9 ± 6.3, respectively. At enrolment, patients were being treated with antihistamines (62.1% of patients), topical corticosteroids (61.3%) and topical moisturising emollients (31.3%). In the year prior, 37.5% of patients had one to three outpatient visits (cost per visit 662.3 ± 1563.4 renminbi (RMB) and 12.9% had one to three hospital admissions (cost per hospitalisation 822.4 ± 3149.2 RMB).</p><p><strong>Conclusions: </strong>Patients in China aged ≥ 12 years with moderate-to-severe AD uncontrolled on topical therapy experience considerable disease burden.</p><p><strong>Clinicaltrial: </strong></p><p><strong>Gov identifier: </strong>NCT05023668.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimal Itch Response in Adults Treated with Dupilumab for Moderate-to-Severe Atopic Dermatitis.","authors":"Sonja Ständer, Gil Yosipovitch, Brian S Kim, Martin Steinhoff, April Armstrong, Franz J Legat, Kenji Kabashima, Takeshi Nakahara, Atsuyuki Igarashi, Amy H Praestgaard, Tien V Nguyen, Mike Bastian","doi":"10.1007/s13555-025-01519-7","DOIUrl":"https://doi.org/10.1007/s13555-025-01519-7","url":null,"abstract":"<p><strong>Introduction: </strong>Itch control is an important treatment goal for patients with atopic dermatitis (AD). According to the treat-to-target framework, optimal treatment goals in AD were defined for various disease domains (e.g., achievement of Eczema Area and Severity Index [EASI] ≤ 7, Peak Pruritus Numeric Rating Scale [PP-NRS] ≤ 4, and Dermatology Life Quality Index [DLQI] ≤ 5) to be achieved after 6 months and sustained thereafter.</p><p><strong>Methods: </strong>In this post hoc analysis of LIBERTY AD CHRONOS (NCT02260986), we report the proportion of patients achieving an optimal itch response with or without an optimal response in signs (EASI ≤ 7) and quality of life (DLQI ≤ 5), after 24 and 52 weeks of treatment with dupilumab.</p><p><strong>Results: </strong>The majority of patients (69 of 90; 76.7%) had an optimal itch response at week 24 as measured by treat-to-target goal PP-NRS ≤ 4; this proportion was sustained at week 52 (64 of 79; 81.0%). Using SCORing Atopic Dermatitis (SCORAD) Pruritus Visual Analog Scale (VAS) < 4 as validation, the majority of patients (76/89; 85.4%) had an optimal itch response at week 24, and this proportion was also sustained at week 52 (69 of 79; 87.3%). Around 70% of patients with an optimal itch response according to PP-NRS or SCORAD Pruritus VAS also had optimal response in EASI and DLQI at weeks 24 and 52.</p><p><strong>Conclusion: </strong>Dupilumab provided optimal itch response and further optimal treatment response in signs and quality of life at week 24, sustained up to 52 weeks, in the majority of patients. Graphical Abstract available for this article.</p><p><strong>Trial registration: </strong>NCT02260986.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence.","authors":"Eduardo Anitua, Roberto Tierno, Mohammad Hamdan Alkhraisat","doi":"10.1007/s13555-025-01542-8","DOIUrl":"https://doi.org/10.1007/s13555-025-01542-8","url":null,"abstract":"<p><strong>Introduction: </strong>Alopecia is a common hair loss condition with different treatment modalities. Platelet-rich plasma (PRP), a minimally invasive autologous therapy, has emerged as a topic of interest, but its effectiveness remains debated. The present systematic review and meta-analysis aims to evaluate the safety and efficacy of PRP for alopecia.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, EMBASE, and Scopus conducted on 27 May 2025 with monthly updates until July 10 2025 identified 43 randomized controlled trials (1877 participants) assessing PRP in alopecia. Primary outcomes were changes in hair density and thickness. Secondary outcomes included side effects, hair loss, clinical improvement, patient satisfaction, recurrence, and other hair follicle metrics.</p><p><strong>Results: </strong>Activated PRP was effective in increasing hair density and minimizing recurrence compared with placebo, whereas non-activated PRP was associated with a higher frequency of adverse effects. PRP also improved clinical outcomes and patient satisfaction. Moreover, hair loss decreased with PRP therapy regardless of activation status or control type. However, PRP did not significantly affect hair thickness. However, PRP did not significantly affect hair thickness.</p><p><strong>Discussion: </strong>These findings support PRP as a relatively safe and effective therapy for alopecia, particularly in increasing hair density and reducing hair loss. Patient satisfaction was generally favorable. The clinical efficacy of PRP was often comparable or superior to conventional treatments. Activation status appears to influence response, highlighting the importance of preparation protocols. However, as a result of heterogeneity in study designs and incomplete reporting of the effect of specific PRP composition-related covariates on treatment efficacy or patient safety outcomes, no significant variation in overall effect modification was attributable to alopecia subtype.</p><p><strong>Conclusions: </strong>Moderate evidence highlights that PRP is safe and effective in improving hair density, reducing hair loss, and enhancing clinical outcomes and satisfaction. No significant benefits were demonstrated for hair thickness or other follicle-related parameters as derived from PRP therapy. Further high-quality, standardized trials are needed to confirm these findings and clarify the clinical significance of PRP formulations.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Literature Reviews on the Disease Burden of Pediatric Psoriasis.","authors":"Santiago Zuluaga Sanchez, Tiffanie Tran, Andrea Garcia, Vyshnavi Telukuntla, Sumi Pillai, Jake Horgan, Cynthia Deignan","doi":"10.1007/s13555-025-01541-9","DOIUrl":"https://doi.org/10.1007/s13555-025-01541-9","url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric psoriasis is a chronic, inflammatory skin disease that substantially impacts the quality of life (QoL) of affected children and their families. Despite numerous literature reviews on psoriasis, data on pediatric populations remain sparse. We aimed to systematically identify and synthesize evidence on the epidemiological, humanistic, and economic burden of pediatric psoriasis, focusing on moderate-to-severe cases.</p><p><strong>Methods: </strong>We conducted two systematic literature reviews (SLRs) of studies on pediatric psoriasis: one focusing on the epidemiological and disease burden of psoriasis of any severity, and one focusing on the humanistic and economic burden in moderate-to-severe psoriasis only. Data were collected from multiple databases, supplemented by additional sources.</p><p><strong>Results: </strong>We identified 56 studies across two SLRs, including interventional studies and observational real-world data from diverse geographic regions. The findings are consistent with the characterization of pediatric psoriasis as a multisystem disease, with higher burden in more severe cases. Prevalence appears to increase with age, and key risk factors are commonly associated with obesity and asthma. Comorbidities span mental health (depression, anxiety), metabolic (obesity, diabetes, hyperlipidemia), musculoskeletal (psoriatic arthritis), and gastrointestinal (celiac disease, ulcerative colitis, Crohn's disease) conditions. Disease severity correlates with higher rates of metabolic syndrome, poorer health-related QoL, and increased caregiver burden, including emotional distress and sleep disturbances. Economic data were limited, with no comprehensive cost-effectiveness analyses or utility measures identified.</p><p><strong>Conclusions: </strong>Our findings indicate limited evidence on the full spectrum of the pediatric psoriasis burden, particularly in moderate-to-severe psoriasis. Data are limited on the prevalence of moderate-to-severe cases, as well as healthcare resource utilization and economic impacts in this population, highlighting the need for further research to inform disease management and resource allocation. Emerging therapies may improve the lives of affected children and their caregivers, but further research is needed to fully capture their potential benefits.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Onset of Atopic Comorbidities Relative to Atopic Dermatitis in Pediatric Patients.","authors":"Yael A Leshem, Clara Weil, William W Busse, Lisa A Beck, Gabriel Chodick, Sonya L Cyr, Kwinten Bosman, Robert Lubwama","doi":"10.1007/s13555-025-01522-y","DOIUrl":"https://doi.org/10.1007/s13555-025-01522-y","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with atopic dermatitis (AD) have a high atopic comorbidity burden. Although traditionally seen as beginning with AD and progressing to other atopic comorbidities, the \"atopic march\" model does not fit all patients. This manuscript describes the onset of atopic comorbidities among children newly diagnosed with AD.</p><p><strong>Methods: </strong>This retrospective, observational, cohort study used data from the Israeli Maccabi Healthcare Services. Patients (< 18 years) first diagnosed with AD during 2000-2019 with ≥ 12-month enrollment before and after AD diagnosis were included. Outcomes included cumulative asthma, allergic rhinitis (AR), and food allergy (FA) prevalence. Patients were grouped by age at AD diagnosis (< 3, 3-5, 6-11, and 12-17 years).</p><p><strong>Results: </strong>Of 177,081 included patients, 60.4% were < 3 years old at AD diagnosis. The baseline asthma prevalence (at or before AD diagnosis) was lower in children aged < 3 versus ≥ 3 years at AD diagnosis (10.6% versus 26.3-28.5%). The baseline AR prevalence increased with age from 2.2% (< 3 years) to 23.2% (12-17 years), while FA decreased from 4.9% (< 3 years) to 2.1% (12-17 years). Cumulative asthma and FA prevalence increased sharply in the year following AD diagnosis among children diagnosed at < 3 years old. The cumulative ≥ 1 asthma/AR/FA prevalence increased to approximately 50% by 10 years after AD diagnosis.</p><p><strong>Conclusions: </strong>Children diagnosed with AD at an early age mostly acquire atopic comorbidities within 1 year following AD diagnosis, while children diagnosed later have often already developed them. Eventually, all pediatric patients with AD display a similar, significant burden of atopic multimorbidity. Graphical abstract available for this article.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145039324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Psoriasis Treatment with Tildrakizumab: Current Evidence and Expert Recommendations for Treatment Individualization in Clinical Practice.","authors":"Ricardo Ruiz-Villaverde, Almudena Mateu, Pedro Mendes-Bastos, Tiago Torres","doi":"10.1007/s13555-025-01538-4","DOIUrl":"https://doi.org/10.1007/s13555-025-01538-4","url":null,"abstract":"<p><p>Psoriasis is a chronic immune-driven inflammatory condition that affects millions of people worldwide. Biologics appeared in the recent years to offer an effective treatment for moderate-to-severe plaque psoriasis. Their efficacy, however, is influenced by patient characteristics, such as obesity, disease severity or prior failure to biologic therapy. This review focuses on the current management of moderate-to-severe plaque psoriasis using tildrakizumab, the only interleukin-23p19 inhibitor offering two dosing options (100 mg or 200 mg) according to individual patient characteristics (high disease burden/body weight). It examines clinical data on the efficacy and effectiveness of both doses and identifies patient profiles that benefit most from tildrakizumab 100 mg or 200 mg. The manuscript also presents practical recommendations to help dermatologists individualize treatment, particularly guiding the appropriate use of the 200 mg dose in routine clinical practice.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145032975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Patient-Reported Outcomes in Chronic Pruritus: Patients with Chronic Liver or Kidney Diseases Exhibit Higher Psychological Distress than Those with Atopic Dermatitis.","authors":"Svenja Royeck, Christian Mess, Angelika Weigel, Bernd Löwe, Anne Toussaint, Christoph Schramm, Meike Shedden Mora, Tobias B Huber, Claudia Zeidler, Felix Witte, Matthias Augustin, Konstantin Agelopoulos, Henning Wiegmann, Johannes B Oehm, Stefan W Schneider, Sonja Ständer","doi":"10.1007/s13555-025-01539-3","DOIUrl":"https://doi.org/10.1007/s13555-025-01539-3","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic pruritus (CP; lasting ≥ 6 weeks) is a prevalent symptom with diverse underlying conditions, including chronic liver diseases (CLD), chronic kidney diseases (CKD) and atopic dermatitis (AD). CP is linked to a substantial physical, psychological and socioeconomic burden. Despite guideline-recommend therapies, there remains a lack of comprehensive understanding regarding the specific needs, treatment goals and patient-reported outcomes (PRO) of patients with CP across these aetiologies.</p><p><strong>Methods: </strong>To address this gap, this retrospective cohort study analysed anonymized electronic health records from a specialized pruritus centre in Germany, focusing on three matched sub-cohorts, which were compiled from a total cohort of 1998 patients with CLD, CKD and AD to systematically compare disease burden, and treatment priorities.</p><p><strong>Results: </strong>Patients with CLD and CKD exhibited significantly higher psychological distress compared to patients with AD, while patients with AD demonstrated greater quality of life impairment. Treatment goals were largely aligned across all patient groups, with symptom relief, diagnostic clarity and confidence in therapy emerging as top priorities. Significant correlations between patient needs, QoL impairment, levels of anxiety and depression and pruritus intensity were observed across all sub-cohorts.</p><p><strong>Conclusions: </strong>These results highlight the need for holistic, patient-centred management strategies that address both the physical and psychological aspects of CP.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons.","authors":"Stephano Cedirian, Monia Donati, Luca Rapparini, Francesca Pampaloni, Michelangelo La Placa, Rossella Sgarzani, Luca Negosanti, Emanuel Raschi, Michela Starace","doi":"10.1007/s13555-025-01537-5","DOIUrl":"https://doi.org/10.1007/s13555-025-01537-5","url":null,"abstract":"<p><p>Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects. In aesthetic and reconstructive surgery, rapid weight loss induced by these agents has raised concerns regarding facial volume depletion, skin laxity, and impaired wound healing. In addition, perioperative management of patients on GLP-1 RAs requires careful assessment as a result of delayed gastric emptying and the associated potential risk of pulmonary aspiration. This narrative review summarizes current knowledge on the benefit/risk profile of GLP-1 RAs, highlighting their impact for dermatologists and plastic surgeons in relevant contexts.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.","authors":"Emma Guttman-Yassky, Eric Simpson, Ehsanollah Esfandiari, Hirotaka Mano, Jillian Bauer, Prista Charuworn, Kenji Kabashima","doi":"10.1007/s13555-025-01492-1","DOIUrl":"10.1007/s13555-025-01492-1","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory disease characterized by eczematous skin lesions, intense pruritus, skin pain, sleep disruption, and mental health disturbances. There remains a need for a therapeutic option that delivers durable efficacy, safety, and convenient dosing across the AD patient population. This review provides an overview of AD pathogenesis driven by T-cell imbalance and describes a novel therapeutic option targeting the OX40 receptor, a costimulatory molecule expressed specifically on activated T cells. Expression of the OX40 receptor on skin-homing T cells is increased in AD. OX40-mediated activation of pathogenic T cells drives inflammation in AD and is critical for the formation of memory T cells, leading to persistent disease. Rocatinlimab (AMG 451/KHK4083) is a novel T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. By reducing pathogenic T-cell number and activity, rocatinlimab has the potential to limit AD flares and modify the course of disease. Rocatinlimab showed promise for the treatment of moderate-to-severe AD in a phase 2b trial, significantly improving overall disease severity, skin involvement, pruritus, sleep disturbance, and quality of life compared with placebo at week 16. Improvements continued through week 36 during active treatment, and notably, were largely maintained in responders throughout a subsequent 20-week off-treatment period, providing evidence for durable on and off treatment responses. Rocatinlimab has also demonstrated a favorable safety and tolerability profile. A large, global phase 3 program (ROCKET) including eight studies is underway to further assess the efficacy, safety, maintenance of response, extended dosing, and off-treatment durability of rocatinlimab in adults and adolescents with moderate-to-severe AD.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}